Clinical trial
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the…
NCT00320710 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00320710 |
|---|---|
| Title | Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer |
| Official title | A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in in the 2nd Year of Treatment in Patients With Documented Bone Metastases From Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic acid, Placebo |
| Enrollment | 416 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2013 |
| Completion | Jul 1, 2013 |
| First posted | May 3, 2006 |
| Last update posted | Aug 22, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: